Literature DB >> 8981383

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.

S Nyberg1, L Farde, C Halldin.   

Abstract

Olanzapine is a new antipsychotic drug with affinity for 5-HT2, D2, D1, and muscarinic receptors. Positron emission tomography and the radioligands [11C]raclopride and [11C]NMSP were used to measure D2 and 5-HT2 receptor occupancy in three healthy subjects after 10 mg olanzapine orally. After seven hours D2 receptor occupancy was 63%, 62% and 59%, respectively. After 9.5 hours 5-HT2 receptor occupancy was 74%, 86% and 92%. D2 and 5-HT2 receptor occupancy was comparable to that found in patients continuously treated with clozapine. Clinical efficacy has been demonstrated for olanzapine in the dose range 5 to 15 mg per day. Extrapolation from our present observations after a 10 mg single-dose suggest, that at the lower end of the clinically examined dose range the D2 and 5-HT2 receptor occupancy should be similar to that induced by standard doses of clozapine. Detailed evaluation of the dose-response characteristics of olanzapine and direct clinical comparison to clozapine will thus provide valuable leads to the clarification of atypical antipsychotic action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8981383     DOI: 10.1016/S0893-133X(96)00218-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  12 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

3.  D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.

Authors:  Mark E Schmidt; Peter de Boer; Randolph Andrews; Martine Neyens; Stefaan Rossenu; Demiana William Falteos; Erik Mannaert
Journal:  Psychopharmacology (Berl)       Date:  2012-07-07       Impact factor: 4.530

4.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers.

Authors:  Hirotoshi Sato; Chihiro Ito; Kotaro Hiraoka; Manabu Tashiro; Katsuhiko Shibuya; Yoshihito Funaki; Takeo Yoshikawa; Ren Iwata; Hiroo Matsuoka; Kazuhiko Yanai
Journal:  Psychopharmacology (Berl)       Date:  2015-07-07       Impact factor: 4.530

7.  Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

8.  Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers.

Authors:  Maria-João Ribeiro; Marcel Ricard; Sandrine Bourgeois; Marie-Angele Lièvre; Michel Bottlaender; Philippe Gervais; Frédéric Dollé; André Syrota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-20       Impact factor: 9.236

Review 9.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

Authors:  B Fulton; K L Goa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 10.  Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Authors:  J T Callaghan; R F Bergstrom; L R Ptak; C M Beasley
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.